Home Tags Surgery

Tag: surgery

Objective To compare the long term efficacy and safety of rosuvastatin with atorvastatin treatment in adults with coronary artery disease. Design Randomised, open label, multicentre trial. Setting 12 hospitals in South Korea, September 2016 to November 2019. Participants 4400 adults (age ≥19 years) with coronary artery disease. Interventions Participants were assigned to receive either rosuvastatin (n=2204) or atorvastatin (n=2196) using 2×2 factorial randomisation. Main outcome measures The primary outcome was a three year composite of all cause death, myocardial infarction, stroke, or any coronary revascularisation. Secondary outcomes were safety endpoints: new onset diabetes mellitus; hospital admissions due to heart failure; deep vein thrombosis or pulmonary thromboembolism; endovascular revascularisation for peripheral artery disease; aortic intervention or surgery; end stage kidney disease; discontinuation of study drugs owing to intolerance; cataract surgery; and a composite of laboratory detected abnormalities. Results 4341 of the 4400 participants (98.7%) completed the trial. Mean daily dose of study drugs was 17.1 mg (standard deviation (SD) 5.2 mg) in the rosuvastatin group and 36.0 (12.8) mg in the atorvastatin group at three years (P<0.001). The primary outcome occurred in 189 participants (8.7%) in the rosuvastatin group and 178 (8.2%) in the atorvastatin group (hazard ratio 1.06, 95% confidence interval 0.86 to 1.30; P=0.58). The mean low density lipoprotein (LDL) cholesterol level during treatment was 1.8 mmol/L (SD 0.5 mmol/L) in the rosuvastatin group and 1.9 (0.5) mmol/L in the atorvastatin group (P<0.001). The rosuvastatin group had a higher incidence of new onset diabetes mellitus requiring initiation of antidiabetics (7.2% v 5.3%; hazard ratio 1.39, 95% confidence interval 1.03 to 1.87; P=0.03) and cataract surgery (2.5% v 1.5%; 1.66, 1.07 to 2.58; P=0.02). Other safety endpoints did not differ between the two groups. Conclusions In adults with coronary artery disease, rosuvastatin and atorvastatin showed comparable efficacy for the composite outcome of all cause death, myocardial infarction, stroke, or any coronary revascularisation at three years. Rosuvastatin was associated with lower LDL cholesterol levels but a higher risk of new onset diabetes mellitus requiring antidiabetics and cataract surgery compared with atorvastatin. Trial registration ClinicalTrials.gov [NCT02579499][1]. Data will be shared by the corresponding author upon reasonable request. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02579499&atom=%2Fbmj%2F383%2Fbmj-2023-075837.atom
Brazil and Al-Hilal forward Neymar will have surgery after rupturing his anterior cruciate ligament while on international duty.
Unable to secure visas for his family from Venezuela, Alvarado savored a visit from his brother, who told him “everyone is so proud of you.â€
Mateusz Gamrot will fly to Abu Dhabi to serve as the backup for the lightweight title fight between Islam Makhachev and Charles Oliveira when they meet at UFC 294
Nashville and Tampa Bay Kick off 2023-24 NHL Season at 4:30 p.m. CT on ESPN
Former 49ers safety Jimmie Ward had an interesting take on his former quarterback this week.
A long and winding road to recovery is set to reach completion on Monday night when Jamal Adams makes his return from injury for the Seattle Seahawks in their clash against the New York Giants. 
Seahawks safety Jamal Adams says he considered retirement after a season-ending injury in 2022 that left him in a cast for 20 weeks.
Jaguars linebacker Devin Lloyd will miss the team's next two games in London after having thumb surgery, while receiver Zay Jones (knee) is a long shot to play this Sunday against the Falcons at Wembley Stadium.